Amrita Krishnan, MD, City of Hope, Duarte, CA, gives a brief overview of the treatment landscape for multiple myeloma, highlighting recent updates including the approval of a BCMA-targeted chimeric antigen receptor T-cell (CAR-T) therapy, as well as the approvals of melflufen and a BCMA-targeting antibody-drug conjugate. Dr Krishnan also comments on unmet needs in multiple myeloma and how the landscape is moving towards immunotherapies. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.